Trials / Completed
CompletedNCT02808793
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
A Phase 1, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 in Patients With Indolent Systemic Mastocytosis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Allakos Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 study to investigate the safety and tolerability of AK002 in patients with indolent systemic mastocytosis (ISM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK002 |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2016-06-22
- Last updated
- 2019-03-13
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02808793. Inclusion in this directory is not an endorsement.